Relypsa Inc Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 48 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-12-12: Reporting owner VEITINGER KLAUS R DR; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-12-11: Reporting owner VEITINGER KLAUS R DR; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-12-10: Reporting owner VEITINGER KLAUS R DR; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-12-09: Reporting owner Lockey Claire; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-12-12 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,852 27,794 owned after | $4.65 exercise price | 2014-12-12 | |
| 2014-12-11 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −150 37,646 owned after | $4.65 exercise price | 2014-12-12 | |
| 2014-12-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,167 37,796 owned after | $4.65 exercise price | 2014-12-12 | |
| 2014-12-09 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 14,267 owned after | $4.65 exercise price | 2014-12-10 | |
| 2014-11-28 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,107 26,144 owned after | $3.96 exercise price | 2014-12-02 | |
| 2014-11-28 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,107 34,694 owned after | $3.96 exercise price | 2014-12-02 | |
| 2014-11-28 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −786 32,759 owned after | $7.40 exercise price | 2014-12-02 | |
| 2014-11-25 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −799 28,251 owned after | $3.96 exercise price | 2014-11-26 | |
| 2014-11-25 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,585 36,801 owned after | $3.96 exercise price | 2014-11-26 | |
| 2014-11-25 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,616 33,545 owned after | $7.40 exercise price | 2014-11-26 | |
| 2014-11-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 29,050 owned after | $3.96 exercise price | 2014-11-26 | |
| 2014-11-20 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,334 41,963 owned after | $4.65 exercise price | 2014-11-24 | |
| 2014-11-17 | Garland J. Scott Officer (SVP & Chief Commercial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $21.36 exercise price | 2014-11-18 | |
| 2014-11-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 45,297 owned after | $4.65 exercise price | 2014-11-12 | |
| 2014-10-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,500 47,797 owned after | $4.65 exercise price | 2014-10-15 | |
| 2014-09-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,503 44,050 owned after | $3.96 exercise price | 2014-09-25 | |
| 2014-09-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,848 48,386 owned after | $3.96 exercise price | 2014-09-25 | |
| 2014-09-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −649 36,161 owned after | $7.40 exercise price | 2014-09-25 | |
| 2014-09-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,167 50,297 owned after | $4.65 exercise price | 2014-09-11 | |
| 2014-08-29 | Stahl Wilhelm Officer (SVP, Pharmaceutical Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −9,972 50,306 owned after | $3.96 exercise price | 2014-09-03 | |
| 2014-08-29 | Stahl Wilhelm Officer (SVP, Pharmaceutical Operations) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,813 0 owned after | $4.65 exercise price | 2014-09-03 | |
| 2014-08-25 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 36,810 owned after | $7.40 exercise price | 2014-08-26 | |
| 2014-08-22 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,207 56,438 owned after | $3.96 exercise price | 2014-08-26 | |
| 2014-08-22 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,793 41,810 owned after | $7.40 exercise price | 2014-08-26 | |
| 2014-08-14 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | Krasnow Ronald A. Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | BALL KRISTINE M Officer (Chief Financial Officer & SVP) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | Corbett Mary Officer (SVP, Human Resources) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | Stahl Wilhelm Officer (SVP, Pharmaceutical Operations) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +24,500 24,500 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-14 | Orwin John A Director, Officer (President & CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +94,500 94,500 owned after | $27.21 exercise price | 2014-08-18 | |
| 2014-08-11 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,167 54,464 owned after | $4.65 exercise price | 2014-08-12 | |
| 2014-08-08 | Stahl Wilhelm Officer (SVP, Pharmaceutical Operations) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −41,299 44,050 owned after | $3.96 exercise price | 2014-08-12 | |
| 2014-08-08 | Stahl Wilhelm Officer (SVP, Pharmaceutical Operations) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,001 60,278 owned after | $3.96 exercise price | 2014-08-12 | |
| 2014-08-08 | Lockey Claire Officer (See Remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 22,267 owned after | $4.65 exercise price | 2014-08-12 | |
| 2014-07-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,796 46,553 owned after | $3.96 exercise price | 2014-07-24 | |
| 2014-07-24 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −6,204 63,441 owned after | $3.96 exercise price | 2014-07-24 | |
| 2014-07-23 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 55,349 owned after | $3.96 exercise price | 2014-07-24 | |
| 2014-07-22 | Berman Lance Officer (Chief Medical Officer and SVP) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 70,349 owned after | $3.96 exercise price | 2014-07-24 | |
| 2014-07-10 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,167 58,631 owned after | $4.65 exercise price | 2014-07-11 | |
| 2014-06-19 | VEITINGER KLAUS R DR Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,828 3,828 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | Schuetz Thomas J. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,828 3,828 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | MCGIRR DAVID W J Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,828 3,828 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | HASTINGS PAUL J Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,828 3,828 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | Butler John P. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +3,828 3,828 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | SPIEGELMAN DANIEL K Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-06-19 | Hillan Kenneth J. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $23.96 exercise price | 2014-06-23 | |
| 2014-01-30 | Corbett Mary Officer (Senior VP, Human Resources) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $33.76 exercise price | 2014-02-03 |